Expanding the Use of CAR T Therapy With shRNA

Video

The chief executive and chief medical officers of Celyad Oncology discussed the company’s future research and plans.

Celyad Oncology is targeting cancers with a number of allogeneic CAR T-cell therapies. Their lead program, CYAD-211, is currently being evaluated in the phase 1 IMMUNICY trial (NCT04613557).

Celyad presented positive interim data at the European Hematology Association (EHA) 2021 Congress in June 2021 from IMMUNICY that showed dose-dependent engraftment up to dose level 3 of 300 x 106 cells per infusion. 

The company reported that no graft-versus-host disease, dose-limiting toxicities, or CAR T-cell related encephalopathy syndromes have occurred to date. A partial response was seen in 2 of the 5 evaluable patients. CYAD-211 cells were detected by polymerase chain reaction-based methods in all 6 patients with evidence of a dose-dependent increase in cell engraftment.

GeneTherapyLive spoke with Filippo Petti, chief executive officer and chief financial officer, and Charles Morris, MBBS, chief medical officer, Celyad Oncology, about the company's future plans and upcoming research. They also discussed potential future opportunities for their short hairpin RNA platform.

REFERENCE
Celyad Oncology presents updates on allogeneic CAR T clinical candidates and shRNA-based preclinical concepts at research & development day. News release. Celyad Oncology. July 20, 2021. https://www.businesswire.com/news/home/20210720005854/en/Celyad-Oncology-Presents-Updates-on-Allogeneic-CAR-T-Clinical-Candidates-and-shRNA-based-Preclinical-Concepts-at-Research-Development-Day

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.